Article
Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.
Molecular therapy : the journal of the American Society of Gene Therapy - 6 Jul 2022
Yang Ya-Wen, Poudel Bibek, Frederick Julia, Dhillon Poonam, Shrestha Rojesh, Ma Ziyuan, Wu Junnan, Okamoto Koji, Kopp Jeffrey B, Booten Sheri L, Gattis Danielle, Watt Andrew T, Palmer Matthew, Aghajan Mariam, Susztak Katalin
Abstract excerpt
Coding variants (named G1 and G2) in Apolipoprotein L1 (APOL1) can explain most excess risk of kidney disease observed in African American individuals. It has been proposed that risk variant APOL1 dose, such as increased risk variant APOL1 level serves as a trigger (second hit) for disease development. The goal of this study was to determine whether lowering risk variant APOL1 levels protects from disease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.